Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
OBJECTIVE
To assess long-term changes in lipids and lipoproteins concentrations associated with exposure to non-nucleoside reverse transcriptase inhibitors.


METHODS
Long-term analysis of plasma lipid concentrations was performed in patients starting first-line antiretroviral therapy with stavudine (d4T) and lamivudine, and either nevirapine or efavirenz.


RESULTS
Concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides continued to increase, while high-density lipoprotein cholesterol showed a slight decrease compared with earlier reported increases after 48 weeks.


CONCLUSIONS
Changes in body fat distribution expected to occur with continued exposure to d4T could offer a potential explanation for these findings.
van Leth
F
F
International Antiviral Therapy Evaluation Center, Amsterdam, the Netherlands. vanlethf@kncvtbc.nl
Hall
D B
DB
Lange
J M A
JM
Reiss
P
P
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002784:Cholesterol / Q000097:blood; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D019829:Nevirapine / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D008055:Lipids; D008074:Lipoproteins; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D019259:Lamivudine; D002784:Cholesterol; D019829:Nevirapine; D018119:Stavudine; C098320:efavirenz